Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: Biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 23, 2008, Pages 6138-6141

  Chowdhury, Morshed Alam ^a   Abdellatif, Khaled R A ^a   Dong, Ying ^a   Das, Dipankar ^a   Suresh, Mavanur R ^a   Knaus, Edward E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Anti inflammatory activity; Celecoxib analogs; Cyclooxygenase 1, cyclooxygenase 2 and 5 lipoxygenase inhibition; N Hydroxypyridin 2(1H)ones

Indexed keywords

1 (4 AMINOSULFONYLPHENYL) 3 TRIFLUOROMETHYL 5 [4 (1 HYDROXY) 1,2 DIHYDROPYRID 2 ONE] 1H PYRAZOLE; 1 (4 METHYLSULFONYLPHENYL) 3 TRIFLUOROMETHYL 5 [4 (1 HYDROXY) 1,2 DIHYDROPYRID 2 ONE] 1H PYRAZOLE; ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; CAFFEIC ACID; CELECOXIB; CELECOXIB DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; TEPOXALIN; UNCLASSIFIED DRUG; ZILEUTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; NONHUMAN; PAW EDEMA; PHARMACOPHORE; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAFFEIC ACIDS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DRUG DESIGN; EDEMA; FOOT; LIPOXYGENASE INHIBITORS; MOLECULAR STRUCTURE; PYRAZOLES; PYRIDONES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 55649108402     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.10.009     Document Type: Article

References (23)

1. Charlier C., and Michaux C. Eur. J. Med. Chem. 38 (2003) 645
2. Barbey S., Goossens L., Taverne T., Cornet J., Choesmel V., Rouaud C., Gimeno G., Yannic-Arnoult S., Michaux C., Charlier C., Houssin R., and Henichart J.-P. Bioorg. Med. Chem. Lett. 12 (2002) 779
3. Pommery N., Taverne T., Telliez A., Goossens L., Charlier C., Pommery J., Goossens J.-F., Houssin R., Durant F., and Henichart J.-P. J. Med. Chem. 47 (2004) 6195 and reference cited therein
4. McMillan R.M., and Walker E.R.H. Trends Pharmacol. Sci. 13 (1992) 323
5. Ford-Hutchinson A.W., Gresser M., and Young R.N. Annu. Rev. Biochem. 63 (1994) 383
6. Young R.N. Eur. J. Med. Chem. 34 (1999) 671
7. Vila L. Med. Res. Rev. 24 (2004) 399
8. Zhao L., and Funk C.D. Trends Cardiovasc. Med. 14 (2004) 191
9. Dannhardt G., and Laufer S. Curr. Med. Chem. 7 (2000) 1101
10. Praveen Rao P.N., Chen Q.-H., and Knaus E.E. J. Med. Chem. 49 (2006) 1668 and references cited therein
11. Scheen A.J. Rev. Med. Liege 59 (2004) 565
12. Dogné J.-M., Supuran C.T., and Pratico D. J. Med. Chem. 48 (2005) 2251
13. Muri E.M.F., Nieto M.J., Sindelar R.D., and Williamson J.S. Curr. Med. Chem. 9 (2002) 1631
14. Carter G.W., Young P.R., Albert D.H., Bouska J., Dyer R., Bell R.L., Summers J.B., and Brooks D.W. J. Pharmacol. Exp. Ther. 256 (1991) 929
15. Chowdhury M.A., Chen H., Abdellatif K.R., Dong Y., Petruk K.C., and Knaus E.E. Bioorg. Med. Chem. Lett. 18 (2008) 4195
16. Penning T.D., Tally J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Doctor S., Graneto M.J., Lee L.F., Malecha J.W., Miyashiro J.M., Rogers R.S., Rogier D.J., Yu S.S., Anderson G.D., Burton E.G., Cogburn J.N., Gregory S.A., Koboldt C.M., Perkins W.E., Seibert K., Veenhuizen A.W., Zhang Y.Y., and Isakson P.C. J. Med. Chem. 40 (1997) 1347
17. Huang H.-C., Li J.J., Garland D.J., Chamberlain T.S., Reinhard E.J., Manning R.E., Seibert K., Koboldt C.M., Gregory S.A., Anderson G.D., Veenhuizen A.W., Zhang Y., Perkins W.E., Burton E.G., Cogburn J.N., Isakson P.C., and Reitz D.B. J. Med. Chem. 39 (1996) 253
18. Levine R., and Sneed J.K. J. Am. Chem. Soc. 73 (1951) 4478
19. Choi H.-Y., and Yoon S.-H. Bull. Korean Chem. Soc. 20 (1999) 857
20. 2 (25 mL), and the reaction was allowed to proceed with stirring at 25 °C overnight.
21. 50, μM) was calculated from the concentration-inhibition response curve (duplicate determinations).
22. 50 value, μM) was determined using an enzyme immuno assay (EIA) kit (Catalog No. 560101, Cayman Chemical, Ann Arbor, MI, USA) according to our previously reported method. Rao P.N.P., Amini M., Li H., Habeeb A., and Knaus E.E. J. Med. Chem. 46 (2003) 4872
23. In vivo anti-inflammatory assay: The test compounds 11a and 11b and the reference drugs celecoxib and aspirin were evaluated using the in vivo carrageenan-induced rat foot paw edema model reported previously. Winter C.A., Risley E.A., and Nuss G.W. Proc. Soc. Exp. Biol. Med. 111 (1962) 544